Excellent Article
There is an excellent article in today's Philadelphia Enquirer on Senator Arlen Specter. Up until now, his fight with Hodgkin's lymphoma has not been very public and my repeated e-mails asking for an interview have been turned away (too bad I don't live in PA). The article, at http://www.philly.com/mld/inquirer/news/local/12150243.htm, describes Specter as more outspoken & very hard working during his treatment. His advocacy towards cancer cure is now fervent.
Separate notes: we got our copy of Potter - good thing Amazon just sent an e-mail lowering the price by a dollar as I saw it at Target for lower before the extra buck back. I'll be off for about 24 hours ferrying campers so if I don't post hourly please don't worry. :-) If you miss me, you can always leave a comment below as I have not received any comments lately (oh poor me).
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
